Ketamine exerts antidepressant effects and reduces IL-1β and IL-6 levels in rat prefrontal cortex and hippocampus
- PMID: 23596475
- PMCID: PMC3627439
- DOI: 10.3892/etm.2013.930
Ketamine exerts antidepressant effects and reduces IL-1β and IL-6 levels in rat prefrontal cortex and hippocampus
Abstract
Ketamine has fast-acting and robust antidepressant effects in animal models and depressed patients. It has been hypothesized that its underlying mechanism of action is associated with the inflammatory response in the central nervous system. Therefore, the present study was designed to investigate the antidepressant effects of ketamine and the expression of interleukin (IL)-1β and IL-6 in the prefrontal cortex and hippocampus of a rat model. Twenty Wistar rats were randomly divided into 2 groups (each group, n=10); the saline group and the ketamine group. On the 1st day, rats undertook a forced swimming test (FST) for 15 min (pre-test session). On the 2nd day, saline or ketamine was administered intraperitoneally 30 min before the test session. Following this, rats performed another FST for 5 min (test session) and the immobility time was recorded. The rats were then sacrificed, and the prefrontal cortex and hippocampus were harvested for determination of IL-1β and IL-6 levels. Compared with the saline group, ketamine administration significantly decreased the immobility time of rats during the FST (P<0.05). In addition, the ketamine group demonstrated a statistically significant decrease in the expression of IL-1β and IL-6 in rat prefrontal cortex and hippocampus compared with the saline group (P<0.05). Ketamine-induced antidepressant effects are associated with decreased levels of IL-1β and IL-6 in rat prefrontal cortex and hippocampus.
Keywords: antidepressant effects; hippocampus; interleukin-1 β; interleukin-6; ketamine; prefrontal cortex.
Figures



Similar articles
-
Effects of ketamine on lipopolysaccharide-induced depressive-like behavior and the expression of inflammatory cytokines in the rat prefrontal cortex.Mol Med Rep. 2013 Sep;8(3):887-90. doi: 10.3892/mmr.2013.1600. Epub 2013 Jul 24. Mol Med Rep. 2013. PMID: 23900245
-
Tramadol pretreatment enhances ketamine-induced antidepressant effects and increases mammalian target of rapamycin in rat hippocampus and prefrontal cortex.J Biomed Biotechnol. 2012;2012:175619. doi: 10.1155/2012/175619. Epub 2012 Apr 8. J Biomed Biotechnol. 2012. PMID: 22577289 Free PMC article.
-
Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test.Ups J Med Sci. 2013 Mar;118(1):3-8. doi: 10.3109/03009734.2012.724118. Epub 2012 Sep 13. Ups J Med Sci. 2013. PMID: 22970723 Free PMC article.
-
Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex.Eur Psychiatry. 2014 Sep;29(7):419-23. doi: 10.1016/j.eurpsy.2013.10.005. Epub 2013 Dec 8. Eur Psychiatry. 2014. PMID: 24321772
-
Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant.Drug Dev Res. 2016 Nov;77(7):414-422. doi: 10.1002/ddr.21335. Epub 2016 Aug 22. Drug Dev Res. 2016. PMID: 27546787 Review.
Cited by
-
Pro-inflammatory monocyte profile in patients with major depressive disorder and suicide behaviour and how ketamine induces anti-inflammatory M2 macrophages by NMDAR and mTOR.EBioMedicine. 2019 Dec;50:290-305. doi: 10.1016/j.ebiom.2019.10.063. Epub 2019 Nov 18. EBioMedicine. 2019. PMID: 31753725 Free PMC article.
-
Antidepressant mechanisms of ketamine: a review of actions with relevance to treatment-resistance and neuroprogression.Front Neurosci. 2023 Aug 8;17:1223145. doi: 10.3389/fnins.2023.1223145. eCollection 2023. Front Neurosci. 2023. PMID: 37614344 Free PMC article. Review.
-
Isoginkgetin treatment attenuated lipopolysaccharide-induced monoamine neurotransmitter deficiency and depression-like behaviors through downregulating p38/NF-κB signaling pathway and suppressing microglia-induced apoptosis.J Psychopharmacol. 2021 Oct;35(10):1285-1299. doi: 10.1177/02698811211032473. Epub 2021 Jul 19. J Psychopharmacol. 2021. PMID: 34281416 Free PMC article.
-
Ketamine Prevents Inflammation-Induced Reduction of Human Hippocampal Neurogenesis via Inhibiting the Production of Neurotoxic Metabolites of the Kynurenine Pathway.Int J Neuropsychopharmacol. 2024 Oct 1;27(10):pyae041. doi: 10.1093/ijnp/pyae041. Int J Neuropsychopharmacol. 2024. PMID: 39297528 Free PMC article.
-
DSP-6745, a novel 5-hydroxytryptamine modulator with rapid antidepressant, anxiolytic, antipsychotic and procognitive effects.Psychopharmacology (Berl). 2024 Nov;241(11):2223-2239. doi: 10.1007/s00213-024-06629-2. Epub 2024 Jun 10. Psychopharmacology (Berl). 2024. PMID: 38856765
References
-
- Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) JAMA. 2003;289:3095–3105. - PubMed
-
- Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci. 2006;7:137–151. - PubMed
-
- Uppal A, Singh A, Gahtori P, Ghosh SK, Ahmad MZ. Antidepressants: current strategies and future opportunities. Curr Pharm Des. 2010;16:4243–4253. - PubMed
-
- Mitchell AJ. Two-week delay in onset of action of antidepressants: new evidence. Br J Psychiatry. 2006;188:105–106. - PubMed
-
- Wright CE, Strike PC, Brydon L, Steptoe A. Acute inflammation and negative mood: mediation by cytokine activation. Brain Behav Immun. 2005;19:345–350. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous